SRR12202428
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- SPERMATOGENESIS+0.280
- KRAS_SIGNALING_DN+0.270
- MYOGENESIS+0.270
- ANGIOGENESIS+0.260
- APICAL_SURFACE+0.250
- KRAS_SIGNALING_UP+0.220
- HEDGEHOG_SIGNALING+0.210
- TNFA_SIGNALING_VIA_NFKB+0.160
- PANCREAS_BETA_CELLS+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- MYC_TARGETS_V2-0.540
- OXIDATIVE_PHOSPHORYLATION-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.360
- DNA_REPAIR-0.340
- MYC_TARGETS_V1-0.340
- MTORC1_SIGNALING-0.330
- PI3K_AKT_MTOR_SIGNALING-0.330
- GLYCOLYSIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516036 | — | — | 0.853 |
| 2 | 15-109pB4_FFPE | — | — | 0.851 |
| 3 | MNG1123 | — | — | 0.844 |
| 4 | SRR612563 | GTEX | — | 0.837 |
| 5 | SRR661818 | GTEX | — | 0.834 |
| 6 | TCGA-FD-A5BV-01A-11R-A26T-07 | — | — | 0.833 |
| 7 | MNG204 | — | — | 0.832 |
| 8 | SRR4296064 | — | cohortA1 | 0.830 |
| 9 | MNG835 | — | — | 0.828 |
| 10 | SRR1516038 | — | — | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.270 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.050 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |